SignalXSignalX

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) 8-K Current Report: February 26, 2026

Filed: February 26, 2026
Health Care
Surgical & Medical Instruments & Apparatus
INTEGRA LIFESCIENCES HOLDINGS CORP Overview

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

INTEGRA LIFESCIENCES HOLDINGS CORP 8-K Feb 26, 2026 Event Analysis

Item 2.02 · Results of Operations and Financial Condition

  • • Earnings release covers Q4 and full-year periods ended December 31, 2025; reconciliation tables included in press release exhibit
  • • Goodwill impairment charges excluded from adjusted results — triggered by tariff uncertainty, quality/operational issues, and market cap decline, signaling material business stress
  • • Boston facility recall charges (products distributed March 2018–May 2023) and Braintree transition costs continue to be excluded from adjusted metrics
  • • Forward-looking guidance provided only on organic revenue and adjusted EPS basis — no GAAP reconciliation provided due to high variability in FX, M&A, and restructuring items
  • • Multiple recurring "non-recurring" exclusions (structural optimization, EU MDR, acquisition costs) warrant scrutiny of how much adjusted EPS diverges from GAAP EPS

Get deeper insights on INTEGRA LIFESCIENCES HOLDINGS CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.